Arvinas, Inc. (ARVN) saw its shares jump 6.9% on the last trading session, closing at $11.33. This positive movement followed a significantly high trading volume and comes after a 20.7% decline over the prior four weeks. The surge is attributed to favorable investor expectations concerning its drug pipeline, particularly positive data shared last month on ARV-102, an experimental target for LRRK2 in Parkinson’s disease treatment.
In the early-stage study, ARV-102 demonstrated a 50% or greater reduction of LRRK2 in cerebrospinal fluid by day 14, sustained through day 28. Despite this, the company forecasts a quarterly loss of $0.94 per share, a 182.5% decline year-over-year, with expected revenues at $17.09 million, a drop of 91% from last year. The earnings consensus estimate has also been revised down by 1.3% over the last month.
Arvinas currently holds a Zacks Rank of #3 (Hold). Another company in the same industry, EyePoint, Inc. (EYPT), also faced a decline, closing up 1% at $13.02, with a month-long return of -29.6%. EyePoint expects an EPS of -$0.79 for its upcoming report, down 21.5% from the previous year.
